These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 29177557)

  • 1. Can checkpoint inhibitor therapy improve response to chemotherapy?
    Kirchberger MC; Schilling B; Haferkamp S; Bosserhoff A; Schuler G; Heinzerling L
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):183-185. PubMed ID: 29177557
    [No Abstract]   [Full Text] [Related]  

  • 2. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma.
    Suryavanshi M; Shah A; Kumar D; Panigrahi MK; Metha A; Batra U
    Oncol Res Treat; 2017; 40(4):198-202. PubMed ID: 28324883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
    J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
    Kim S; Koh J; Kwon D; Keam B; Go H; Kim YA; Jeon YK; Chung DH
    Eur J Cancer; 2017 Apr; 75():141-149. PubMed ID: 28222308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
    Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma].
    Schwab R; Peták I; Pintér F; Szabó E; Kánya M; Tamási A; Várkondi E; Almási A; Szokolóczi O; Pápay J; Moldvay J; Kéri G; Kopper L
    Orv Hetil; 2005 Nov; 146(46):2335-42. PubMed ID: 16370245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of advances in treatment for advanced non-small cell lung cancer.
    Gettinger S; Lynch T
    Clin Chest Med; 2011 Dec; 32(4):839-51. PubMed ID: 22054890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
    Zhang B; Liu ZM; Hao FG; Wang M
    Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
    Drosten M; Barbacid M
    J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
    Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
    Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab.
    Russo I; Sacco G; Frega S; Polo V; Pasello G; Alaibac M
    Eur J Dermatol; 2017 Apr; 27(2):205-208. PubMed ID: 28251900
    [No Abstract]   [Full Text] [Related]  

  • 15. Lung cancer.
    Hansen HH; Rørth M
    Cancer Chemother Biol Response Modif; 1991; 12():443-59. PubMed ID: 1657089
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical results with immunochemotherapy in 40 cases of advanced tumour.
    Narcisi M
    Panminerva Med; 1975; 17(5-6):208-10. PubMed ID: 1161322
    [No Abstract]   [Full Text] [Related]  

  • 17. Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells.
    Shang B; Jia Y; Chen G; Wang Z
    Respir Res; 2017 Apr; 18(1):56. PubMed ID: 28399858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for lung cancers: here to stay.
    Kris MG; Hellmann MD; Chaft JE
    Am Soc Clin Oncol Educ Book; 2014; ():e375-80. PubMed ID: 24857127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the understanding and treatment of melanoma -- Keystone Symposium.
    Sondak VK
    IDrugs; 2006 Mar; 9(3):157-60. PubMed ID: 16523374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.